Podcasts

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Vibeke Strand, Adjunct Clinical Professor at the Division of Immunology and Rheumatology at Stanford University School of Medicine in California. Together, they discuss the efficacy and safety of upadacitinib and elsubrutinib combination and monotherapy, as well as the association of LLDAS with improved outcomes in SLE.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Vibeke Strand, Adjunct Clinical Professor at the Division of Immunology and Rheumatology at Stanford University School of Medicine in California. Together, they discuss predictors of belimumab renal response in lupus nephritis, and the efficacy and safety of telitacicept in SLE with haematological involvement.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Brad Rovin, Professor of Nephrology and Medical Director of the Ohio State University Clinical Research Management Institute. Together, they discuss the use of belimumab to reduce prednisone doses and the development of the SLESIS-R score for determining the risk of severe infection in SLE.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Victoria Werth, Professor of Dermatology and Medicine, University of Pennsylvania and Philadelphia Veterans Administration Hospital. Together, they discuss the latest developments in CAR T-cell therapy, development of Smith-specific regulatory T cells, and cardiovascular risk factors.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Chris Edwards, Consultant Rheumatologist and Honorary Chair of Clinical Rheumatology University Hospital Southampton, UK. Together, they discuss the latest developments and perspectives in glucocorticoid tapering, TYK2 therapy in rheumatic disease, as well as SLE QoL and LLDAS.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Maria Dall’Era, Professor of Medicine and Chief of the Division of Rheumatology at the University of California in San Francisco, USA. Together, they discuss latest developments and perspectives in RNase therapy and patient-reported outcome quality measures in SLE, as well as serological predictors of renal flares.